Program
ruxolitinib
Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.
Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.
Drug pageRuxolitinib: every studyAll 302 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyteits history only | 689 open or running | phase 4since Jan 13, 2023 | Jul 30, 2007 | Dec 9, 2026phase 1 · NCT07049575 |
| Novartisits history only | 214 open or running | phase 4since Mar 16, 2012 | Jul 6, 2009 | May 10, 2029phase 4 · NCT06824103 |
| Suzhou Junjing BioSciences | 11 open or running | phase 2since Mar 27, 2025 | Mar 27, 2025 | Oct 31, 2027phase 2 · NCT06909136 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Suzhou Junjing BioSciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2025First study: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyFirst studyNCT06909136 · 33 enrolled · China
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyNCT06909136
TargetBeta
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
The one study Suzhou Junjing BioSciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06909136Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly · China | 2 | Active, not recruiting | Oct 31, 2027 | 33 |
How it is read
Names in the registry
- “Ruxolitinib”, 44 entries
- “Ruxolitinib cream”, 14 entries
- “Ruxolitinib Cream”, 11 entries
- “ruxolitinib”, 6 entries
- “Ruxolitinib phosphate cream”, 4 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 20 studies
- Dermatitis, Atopic, 13 studies
- Vitiligo, 9 studies
- Graft vs Host Disease, 8 studies
- Pancreatic Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.